SCHEMBL6453986

SCHEMBL6453986

COc1cc2c(cc1OC)C1CCCCC1N=C2c1ccsc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 9/20 0.40
PDE4A P27815 8/20 0.38
PDE4B Q07343 7/20 0.38
PDE4C Q08493 7/20 0.38
PDGFRB P09619 2/20 0.38
PDGFRA P16234 2/20 0.38
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.35
CHRM1 P11229 1/20 0.35
KMT2A Q03164 1/20 0.35
PDE3A Q14432 1/20 0.35
MAPK1 P28482 1/20 0.34
P2RX3 P56373 2/20 0.33
TACR1 P25103 1/20 0.33
SIK1 P57059 1/20 0.33
SIK2 Q9H0K1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6453982 1.00 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPDGFRB
SCHEMBL6453976 1.00 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPDGFRB
SCHEMBL5563183 0.83 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPOLB
SCHEMBL5563191 0.83 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPOLB
SCHEMBL5563196 0.83 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CPOLB
SCHEMBL6449710 0.79 RPS6KB2 (0.41) PDE4DPDGFRBPDGFRAHTTMEN1
SCHEMBL6449709 0.79 RPS6KB2 (0.41) PDE4DPDGFRBPDGFRAHTTMEN1
SCHEMBL6442469 0.79 PDE4D (0.42) PDE4DPDE4APDE4BPDE4CCYP1A2
SCHEMBL6442473 0.79 PDE4D (0.42) PDE4DPDE4APDE4BPDE4CCYP1A2
SCHEMBL6449706 0.79 RPS6KB2 (0.41) PDE4DPDGFRBPDGFRAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884802-B2 6-heteroarylphenanthridines ALTANA PHARMA AG (DE) 2005-04-26 US disclosed
US-20040038979-A1 Treating airway disorders such as asthma. ALTANA PHARMA AG (DE) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038979-A1 Treating airway disorders such as asthma. PTGER4, PDE4B, PDE4A PDE4D 20/4885PDE4A 3/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.